While previous studies with investigational NASH agents that have reached clinical testing have reported body weight, liver weight, plasma lipids, AST, ALT, or histological findings27–30, only GLP-1 based approaches have been associated with significant weight loss in published trials to date. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.